Victory Capital Management
HRTX icon

Victory Capital Management’s Heron Therapeutics HRTX Stock Holding History

Victory Capital Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.63K Sell
20,226
-1,007
-5% -$807 ﹤0.01% 2468
2026
Q1 		$17K Buy
21,233
+319
+2% +$370 ﹤0.01% 2380
2025
Q4 		$27.2K Buy
20,914
+29
+0.1% +$36 ﹤0.01% 2369
2025
Q3 		$26.3K Buy
20,885
+2,863
+16% +$4.54K ﹤0.01% 2383
2025
Q2 		$37.3K Sell
18,022
-187
-1% -$382 ﹤0.01% 2406
2025
Q1 		$40.1K Sell
18,209
-471
-3% -$914 ﹤0.01% 2385
2024
Q4 		$28.6K Buy
18,680
+398
+2% +$645 ﹤0.01% 2429
2024
Q3 		$36.4K Buy
18,282
+270
+1% +$645 ﹤0.01% 2410
2024
Q2 		$63K Sell
18,012
-750
-4% -$2.3K ﹤0.01% 2344
2024
Q1 		$52K Sell
18,762
-1,167
-6% -$2.93K ﹤0.01% 2375
2023
Q4 		$33.9K Buy
19,929
+4,617
+30% +$5.08K ﹤0.01% 2473
2023
Q3 		$15.8K Buy
15,312
+2,424
+19% +$3.45K ﹤0.01% 2461
2023
Q2 		$14.9K Sell
12,888
-299
-2% -$533 ﹤0.01% 2465
2023
Q1 		$19.9K Sell
13,187
-171
-1% -$428 ﹤0.01% 2509
2022
Q4 		$33.4K Buy
13,358
+1,705
+15% +$5.49K ﹤0.01% 2485
2022
Q3 		$49K Sell
11,653
-1,161
-9% -$4.54K ﹤0.01% 2568
2022
Q2 		$36K Sell
12,814
-44
-0.3% -$177 ﹤0.01% 2578
2022
Q1 		$58K Sell
12,858
-1,081
-8% -$7.91K ﹤0.01% 2583
2021
Q4 		$127K Sell
13,939
-430
-3% -$4.39K ﹤0.01% 2544
2021
Q3 		$154K Sell
14,369
-714
-5% -$8.69K ﹤0.01% 2569
2021
Q2 		$234K Buy
15,083
+1,125
+8% +$17.9K ﹤0.01% 2495
2021
Q1 		$226K Sell
13,958
-349
-2% -$6.22K ﹤0.01% 2497
2020
Q4 		$303K Buy
14,307
+730
+5% +$12.7K ﹤0.01% 2281
2020
Q3 		$201K Buy
+13,577
New +$212K ﹤0.01% 2286

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Victory Capital Management's HRTX Position: Q2 2026 in Review

Victory Capital Management reduced its Heron Therapeutics (HRTX) stake by 4.7% in Q2 2026, selling an estimated $807 and leaving 20,226 shares worth $8.63K. The position accounts for ﹤0.01% of the portfolio, ranked #2468.

Victory Capital Management first reported a position in HRTX in Q3 2020 and has held it in 24 quarters since. The position peaked at $303K in Q4 2020. 163 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • Victory Capital Management held 20,226 shares of Heron Therapeutics worth $8.63K as of Q2 2026.
  • Victory Capital Management sold 1,007 Heron Therapeutics shares in Q2 2026, an estimated $807.
  • Heron Therapeutics made up ﹤0.01% of Victory Capital Management's portfolio in Q2 2026, its #2468 holding.
  • Victory Capital Management first reported a position in Heron Therapeutics in Q3 2020 and has held it in 24 quarters since.
  • Victory Capital Management's Heron Therapeutics position peaked at $303K in Q4 2020.
  • 163 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on Victory Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.